Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638251 | 0.87 | DRD2 (0.40) | BCHERORCCA1CA2ACHE | |
| SCHEMBL12509872 | 0.85 | LMNA (0.41) | — | |
| SCHEMBL1638613 | 0.83 | LOXL2 (0.41) | RORC | |
| SCHEMBL19631329 | 0.79 | HDAC3 (0.47) | BCHECA1CA2L3MBTL1CA4 | |
| SCHEMBL25259191 | 0.79 | ALDH1A1 (0.49) | BCHEL3MBTL1ACHE | |
| SCHEMBL22778380 | 0.79 | ALDH1A1 (0.49) | CA1CA2L3MBTL1CA4ACKR3 | |
| SCHEMBL4847536 | 0.79 | RORC (0.50) | BCHERORCL3MBTL1ACHE | |
| SCHEMBL19862468 | 0.78 | ALOX5 (0.51) | BCHEL3MBTL1 | |
| SCHEMBL7571319 | 0.77 | ALDH1A1 (0.59) | CA1CA2L3MBTL1CA4 | |
| SCHEMBL12426460 | 0.77 | BCHE (0.37) | BCHERORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977512-B2 | Amine derivative, and production method and use thereof | KUREHA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | KUREHA CORPORATION | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293951-A1 | Amin Derivative, and Production Method and Use Thereof | BCAT2, BCAT1, MRPL9 | BCHE 235/4885RORC 4375/4885CA1 3598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.